Zobrazeno 1 - 10
of 2 937
pro vyhledávání: ''
Autor:
Xiao Xiao, Wei-Xiong Xia, Shaomin Huang, Jingjing Miao, Fei Han, Lin Wang, Xiang Guo, Yan-Qun Xiang, Chong Zhao, Yinglin Peng, Boyu Chen, Xiaowu Deng, Huageng Huang, Xing Lv, Yingshan Liang, Manyi Zhu, Weiwei Xiao
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose This study was aimed to investigate long-term survivals and toxicities of early-stage nasopharyngeal carcinoma (NPC) in endemic area, evaluating the role of chemotherapy in stage II patients.Materials and Methods Totally 187 patients with new
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was condu
Autor:
Isabelle Ghelerter, Marie-Hélène Lafeuille, Mike Durkin, Joyce LaMori, Patrick Lefebvre, Lorie Ellis, Carmine Rossi, Dominic Pilon, Xuehua Ke
Publikováno v:
Future Oncology. 18:231-243
Aims: In light of the extended overall survival and improved quality of life provided by advanced prostate cancer (PC) oral therapies, this study aimed to describe treatment adherence to advanced PC oral therapies and evaluate associated patient char
Autor:
Jonn Wu, Cheryl Ho, Zamzam Al-Hashami, Bonnie Leung, S. Moore, Selina K. Wong, Alexandra Pender, Ying Wang, Aria Shokoohi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
Cancer Medicine, Vol 11, Iss 1, Pp 86-93 (2022)
The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC) has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The study goal was to assess the effect of molecular testing and the introduc
Autor:
Courtney Nicole Miller-Chism, Harinder S. Juneja, Curtis Lachowiez, Hilary Y. Ma, Martha P. Mims, Wei Qiao, Onyebuchi Ononogbu, Mark M. Udden, Effrosyni Apostolidou
Publikováno v:
Clin Lymphoma Myeloma Leuk
Despite therapeutic advances and improvement in outcomes of patients with acute lymphoblastic leukemia, as reported by specialized centers, healthcare disparities exist. This is a retrospective cohort analysis of the clinical outcomes of 146 patients
Autor:
Boris Kollárik, Michal Mego, Zuzana Sycova-Mila, Jozef Mardiak, Jan Slopovsky, Katarina Rejlekova, Michal Chovanec, Patrik Palacka, Jana Obertova
Publikováno v:
Anticancer Research. 41:5749-5759
BACKGROUND/AIM Systemic immune-inflammation index (SII) predicts survival of patients with various malignancies. This study explored the prognostic value of SII in metastatic urothelial carcinoma (MUC) subjects. PATIENTS AND METHODS We evaluated 181
Publikováno v:
Clinical Lung Cancer. 22:e808-e816
Background Conflicting data exists regarding the benefit of prophylactic cranial irradiation (PCI) in patients with extensive-stage small-cell lung cancer (ES-SCLC). We sought to retrospectively review outcomes of patients within our network with ES-
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Autor:
Mitsunobu Otsuru, Hiroshi Kurita, Nobuhiro Yamakawa, Masahiro Umeda, Masaya Okura, Tomofumi Naruse, Yoshihide Ota, Tadaaki Kirita, Masashi Sasaki, Souichi Yanamoto, Shin-ichi Yamada, Yukari Shintani, Tatsushi Matsumura
Publikováno v:
Anticancer Research. 41:5785-5791
Background/aim This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M OSCC).
Publikováno v:
Anticancer Research. 41:5569-5575
Background/aim While controversial, cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) and early postoperative intra-peritoneal chemotherapy (EPIC) remains the mainstay of treatment for low grade appendiceal neoplasm with p